Global Pulmonary Surfactant Market, by Type (Synthetic Pulmonary Surfactant,Animal Derived Surfactant), by Drug Type (Poractant alfa, Lucinactant, Calfactant), by Indications (Respiratory Distress Syndrome (RDS), Respiratory Infections, Obstructive lung Diseases, Others(chronic lung disease of prematurity, and surfactant protein-B deficiency)), by Route of Administration (Intratracheal, Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 578.7 Mn in 2022, and is expected to exhibit a CAGR of 4.50% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
To prevent and treat infant respiratory distress syndrome (RDS), lungs surfactants are given. Over 40,000 infants in the U.S. and Canada suffer with RDS each year, a significant side effect of premature delivery. Due to inadequate lung compliance brought on by a functional or quantitative surfactant deficit, the lungs finally collapse. By stabilising alveoli and lowering surface tension, surfactant, a mixture of neutral lipids, neutral phospholipids, and proteins produced by pneumocytes during pregnancy, improves lung compliance and shortening of breath.
Increase rate of prevalence of various lung disease is driving the growth of the global pulmonary surfactant market. For instance, on May 11, 2022, the World Health Organization published a report which stated that asthma is a major noncommunicable disease (NCD), affecting both children and adults, and is the most common chronic disease among children, which leads to Inflammation and narrowing of the small airways in the lungs cause asthma symptoms such as cough, wheeze, shortness of breath, and chest tightness. Moreover from the same source, asthma affected an estimated 262 million people in 2019 and caused 455,000 deaths globally.
The potential for strategizing pulmonary surfactant (PS) for drug delivery over the respiratory air-liquid interface, the interfacial delivery is expected to drive the global pulmonary surfactant market. For instance, according to the report published in Jan 2021, by National Center for Biotechnology Information, the United States National Library of Medicine, reported that the use of Pulmonary Surfactant as a drug delivery system was highly promising, with pulmonary surfactant transporting the drug potentially by surfing the air-liquid interface towards the distal Airways, also breathing dynamics contributing to drug diffusion and release together with surfactant components and clearing mechanisms promoting the uptake of surfactant components and drug by alveolar macrophages.
Global Pulmonary Surfactant Market– Impact of Coronavirus (COVID-19) Pandemic
The coronavirus or COVID-19 outbreak started in Wuhan, China in 2019 and has spread across all the continents of the world, affecting various industries globally. The economy in countries all over the world such as India, Italy, Bangladesh, Sri Lanka, the U.S., Morocco, and others has been disrupted due to lockdowns implemented by governments to combat the spread of coronavirus since 2020.
The role of pulmonary surfactant in the treatment of acute respiratory distress syndrome during COVID-19 played a major role. For instance, in June 2021, Frontiers media, a publisher of peer-reviewed open access scientific journals, published a report which stated that SARS-CoV-2 uses ACE-2 (angiotensin converting enzyme) receptor on lungs for entry and (AT) alveolar type II cells(play a key role as part of the distal lung epithelium) for replication. AT II cells are the sites of pulmonary surfactant production. Lack of pulmonary surfactant is the principal cause for NRDS, Newborn respiratory distress syndrome and viral infections are known to reduce Pulmonary Surfactant levels in lungs. PS therapy is the mainstay for NRDS treatment across the world.
Thus, impact of the coronavirus (COVID-19) pandemic has driven growth of the global pulmonary surfactant market during the forecast period.
Global Pulmonary Surfactant Market: Key Developments
Increasing focus on research and development by key players for respiratory diseases is driving the growth of global pulmonary surfactant market. For instance, on February 1, 2022, Windtree Therapeutics, Inc., an U.S. based company developing drug products for patients with respiratory disease, focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced it had completed enrollment in its Phase 2 study of lucinactant, a liquid medication used to treat infant respiratory distress syndrome, (KL4 surfactant) for patients with COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS). The Phase 2 trial is a multicenter, single-treatment study in which 20 patients designed to evaluate the safety and tolerability of lucinactant delivered as a liquid via the endotracheal tube in patients who are mechanically ventilated as a result of COVID-19 associated acute lung injury.
Increasing agreement between the key market players drives the growth of global pulmonary surfactant market. For instance, Aerogen Pharma, a pharmaceutical company entered into an agreement wiith Nuance Pharma, a clinical-stage biopharmaceutical company, to advance treatment of respiratory distress syndrome in premature infants in China. The agreement initiates nuance the exclusive rights to develop and commercialize AeroFact, a new therapy combining a well-established pulmonary surfactant drug with proprietary vibrating mesh nebulizer aerosolization technology, in Greater China (Mainland China, Taiwan, Hong Kong and Macau). The conventional invasively-delivered lung surfactant improved clinical outcomes for the hundreds of thousands of premature babies around the world whose healthy development is threatened by RDS (Respiratory Distress Syndrome).
Browse 39 Market Data Tables and 32 Figures spread through 161 Pages and in-depth TOC on "Global Pulmonary Surfactant Market, by Type (Synthetic Pulmonary Surfactant, Animal Derived Surfactant), by Drug Type (Poractant alfa, Lucinactant, Calfactant), by Indications (Respiratory Distress Syndrome (RDS), Respiratory Infections, Obstructive lung Diseases, Others(chronic lung disease of prematurity, and surfactant protein-B deficiency)), by Route of Administration(Intratracheal, Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), - Global Forecast to 2030”
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/pulmonary-surfactant-market-5324
Key Takeaways of the Global Pulmonary Surfactant Market:
- Global pulmonary surfactant market is expected to witness a CAGR of 4.50% during the forecast period, owing to increasing research and development activities to introduce advancement in pulmonary surfactant market.
- Among type, animal derived surfactant segment is expected to hold a dominant position in market over the forecast period. This is owing to increasing adoption of animal derived surfactant due to lower mortality rate and lower complications. For instance, in June 2020, National Center for Biotechnology Information, U.S. based National Library of Medicine, conducted a study and stated that the patients treated with endobronchial poractant alfa had improvement of the PaO2/FiO2 ratio (to determine the severity of lung injury in mechanically ventilated patients.) and radiological data without any complications during the entire process.
- Among Drug type, Poractant alfa segment is expected to hold a dominant position in market over the forecast period. Due to higher benefits and lower complications. For instance, on January 9, 2022, International Journal of Contemporary Pediatrics, an open access, international, peer-reviewed journal, published a report of study performed on comparison between to natural surfactant poractant alfa and bovine lipid extract for the treatment of respiratory distress syndrome amongst preterm neonates. CUROSURF (poractant alfa) is 6.67% more efficacious than NEOSURF (bovine lipid extract) for need of reduce no of mechanical ventilatio CUROSURF use was associated with less duration of oxygenation, less duration of hospitalization and reduced requirement of mean FiO2 (The fraction of inspired oxygen). CUROSURF needed less repeat doses of surfactant in comparison to NEOSURF.
- Among distribution channel, hospital pharmacies segment is expected to hold dominant position over the forecast period as reimbursement and pricing of drugs are more favorable in hospital pharmacies, owing to 340B pricing program ( Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients)
- Key players operating in the global pulmonary surfactant market include, Boehinger Ingelheim, AbbVie Inc, Chiesi Farmaceutici, ONY Biotech Inc., Lyomark Pharma, Abbott, Aviva Systems Biology Corporation, Windtree Therapeutics, Inc, Tekzima (Noargen), Biomatik, Nanjing Norris Pharm Technology, Reddot Biotech
